Today: 3 July 2026
Tesla stock today: TSLA ends 2025 lower with deliveries report now the next big test
1 January 2026
1 min read

Tesla stock today: TSLA ends 2025 lower with deliveries report now the next big test

NEW YORK, January 1, 2026, 05:51 ET — Market closed.

  • Tesla shares last closed down 1.0% at $449.72 as U.S. markets shut for the New Year’s Day holiday.
  • Investors are focused on Tesla’s quarterly production and delivery report due Friday.
  • Analysts expect a year-on-year drop in deliveries as demand cools and competition tightens.

Tesla shares ended Wednesday down 1.0% at $449.72, and the U.S. stock market is closed Thursday for the New Year’s Day holiday. The next catalyst arrives on Friday, when the company is expected to report quarterly production and deliveries.

The delivery figure — the number of vehicles handed to customers — is the market’s quickest read on demand because Tesla releases it well ahead of quarterly earnings.

That timing matters now because investors often trade Tesla on shifts in unit momentum, even as the company pitches longer-term bets in self-driving technology and a future robotaxi business.

Tesla shares rose over 14% in 2025, but analysts expect the automaker’s fourth-quarter deliveries to fall as the loss of U.S. tax credits and rising global competition weigh on demand, Reuters reported. Analysts polled by Visible Alpha see fourth-quarter deliveries at 432,810 vehicles, down about 13% from a year earlier, while a company-compiled consensus shows 422,850. “The fall will be driven largely by sales in North America and Europe,” Deutsche Bank analyst Edison Yu said in a note; Reuters said Tesla launched lower-priced “Standard” versions of the Model Y and Model 3 in October — about $5,000 below prior base models — and faces cheaper models planned by Chevrolet and Ford. Reuters

The move came as U.S. stocks slipped on the final trading day of 2025, with the S&P 500 down 0.74% and the Dow off 0.63%, according to market data.

Separately, a Form 4 filing showed Chief Executive Elon Musk gifted 210,699 Tesla shares to certain charities as part of year-end tax planning. The filing said the recipients advised Musk they have no current intention to sell the stock.

Before the next session, the focus is Tesla’s production and delivery release due Friday. Investors will watch for any sign that lower-priced trims are supporting volumes without adding fresh pressure on pricing.

Technically, TSLA has fallen for six straight sessions and sits about 10% below its Dec. 22 52-week high of $498.83. Traders often watch round numbers, and the $450 area is now close after Wednesday’s finish.

Tesla has not yet posted the timing for its fourth-quarter earnings release on its investor relations press page. Third-party calendars currently cluster around late January to early February, with Wall Street Horizon listing Jan. 28 as unconfirmed and Nasdaq pegging Feb. 4 as an estimate.

Macro data could add cross-currents for high-growth stocks: the U.S. Labor Department’s schedule shows the December jobs report due Jan. 9 and the December consumer price index report due Jan. 13.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • AbbVie Jumps 4%, Tops Apogee Buy Price After Earnings Beat
    July 2, 2026, 7:16 PM EDT. AbbVie Inc. finished up 3.99% at $261.07, a new 52-week high. The stock gained nearly $17.8 billion in market cap, putting it well above the $10.9 billion Apogee Therapeutics deal announced June 22. AbbVie closed above targets from RBC Capital, Investing.com and Google Finance. With Q2 earnings set for July 31, the rally puts the spotlight on analyst target hikes. J.P. Morgan and RBC Capital have backed the Apogee buy for its long-term growth, with the company saying the acquisition will add to EPS by 2032. AbbVie outpaced broader markets, which slipped slightly, as investors bet on the drugmaker's deal strategy.
Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026
Previous Story

Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next
Next Story

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next

Go toTop